Tzu-Hao Lee, MD
Transplant Hepatology · Houston, TXNPI 1396032546
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,150 of the $4,205 with a category attached, or 74.9%. AbbVie accounts for 75.4% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $3,648, more than ten times the $120 reported in 2022. That places this record below the midpoint for transplant hepatology clinicians in TX, where the typical reported total is $5,913.
Across 12 payments — averaging $350.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Gilead$215
- Cook Medical LLC$204
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$150
- Madrigal Pharmaceuticals$145
- Novo Nordisk$120
- plus $200 from 2 others
What the payments were for
- Consulting fees$3,15075%
- Food & beverage$1,05525%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 2 | $3,171 |
| Gilead | 2 | $215 |
| Cook Medical LLC | 2 | $204 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $150 |
| Madrigal Pharmaceuticals | 1 | $145 |
| Novo Nordisk | 1 | $120 |
| Mallinckrodt Hospital Products Inc. | 1 | $120 |
| Mirum Pharmaceuticals, Inc. | 2 | $80 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIFAXAN$150
- REZDIFFRA$145
- ECHOTIP INSIGHT$123
- TERLIVAZ$120
How this compares
$4,205 in reported general payments places this provider in the 40th percentile of 28 transplant hepatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 17 | $51,647 |
| Entecavir | 11 | $403 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $150 | $51,64717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 28 transplant hepatology providers in Texas.
Other transplant hepatology in Houston
- David VictorHouston$249K
- Prasun JalalHouston$247K
- Kavish PatidarHouston$22K
- Saira KhaderiHouston$9K
- Ruben Hernaez RodriguezHouston$784
- Avegail FloresHouston$702
- Nagasri ShankarHouston$191
- Abdullah MubarakTyler$362K
- Stevan GonzalezFort Worth$282K
- Fernando MembrenoMcAllen$258K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.